alexa Abstract | Chloroquine Resistance and Host Genetic Factors among Nigerian Children with Uncomplicated P.falciparum Infection

Archives of Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Chloroquine resistance and host genetic factors among Nigerian children with uncomplicated P.falciparum infection. Background: Chloroquine resistance is widespread. Host factors play a role in drug resistance. The study aims to determine the association between hosts red cell factors namely G6PD status, ABO blood group and haemoglobin genotype with Pfmdr1 mutations and treatment outcome. Methods: One hundred and twenty patients (aged 1-15years) with acute symptoms of P.falciparum malaria were treated with chloroquine (CQ). Blood sample was obtained for haematological parameters and analysis of parasite DNA. Nested PCR followed by restriction fragment length polymorphism (RFLP) at codon 86 of the Pfmdr1 gene was determined in the 120 isolates. Relationship between Pfmdr1 alleles, CQ resistance, G6PD deficient, sickle cell trait and parasite diversity was evaluated. Results: Seventy of the 120 patients enrolled into this study completed the 14-day follow-up, aged 7.8 ± 4.6 years, 62 (52%) were females with parasites geometric mean 21,861 (range 1000-354,667) asexual parasites per microlitre of blood. Thirtyseven of the 70 (53%) were cured while 47% failed chloroquine treatment; mean parasite clearance time (PCT) was 7.1 days, whereas the mean fever clearance time was 3.4 days. Mutation revealed wild type N86 (56), mutant type Y86 (50) and mixed genotype N86+Y86 (14). No significant correlation was found between Pfmdr1 mutations and in-vivo outcome (p=0.21). About 51% (36/70) of the in-vivo pre-treatment samples carried the Pfmdr1 Y86 mutation and its prevalence varied with age (p=0.017). The Pfmdr1Y86 mutation was detected in majority (19/33) of patients with clinical failure OR=1.711; 95% CI: 0.517-5.668; p=0.378 and was more in younger OR=1.200; 95% CI: 0.782-1.840 than in older children OR=0.818; 95% CI: 0.507-1.321. Conclusion: There is an association between Pfmdr1Y86 mutation and CQ treatment failure which tends to be stronger in younger children. These suggest the role of age and host immunity in modifying the relationship between molecular markers and resistance.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): CM NnejiADA AdedapoPN OkorieOG Ademowo


General Medicine, Heart Disease and Genetics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version